New drug targets genetic weakness in Hard-to-Treat cancers

NCT ID NCT04439175

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial tests the drug taselisib in 70 patients with advanced cancers (excluding breast cancer) that have a specific genetic change called a PIK3CA mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if taselisib can shrink tumors or stop them from growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Taselisib (a drug that blocks a protein called PIK3CA, which may help cancer grow)
What this could lead to: If it works, this could point toward a targeted treatment option for patients with certain genetic mutations in their cancer.
What could go wrong: This is a small, early-phase trial (70 patients) with no control group, so results may not apply broadly. The drug may cause side effects and may not shrink tumors effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm lymphoma plasma cell myeloma refractory hematologic cancer refractory malignant neoplasm refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LYMPHOMA ADVANCED MALIGNANT SOLID NEOPLASM HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM REFRACTORY LYMPHOMA REFRACTORY MALIGNANT SOLID NEOPLASM REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

ECOG-ACRIN Cancer Research Group

Philadelphia, Pennsylvania, 19103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.